Ceraxa
Cancer (HCC, AML, Pancreatic, Prostate, etc.)
Phase 2 ReadyActive
Key Facts
Indication
Cancer (HCC, AML, Pancreatic, Prostate, etc.)
Phase
Phase 2 Ready
Status
Active
Company
About Pendrea Bio
Pendrea Bio is an innovative, early-stage biotech leveraging proprietary nanoparticle platforms to create novel cancer treatments with dual mechanisms of action. Its lead asset, Ceraxa, has completed Phase 1 and shows promise in restoring chemotherapeutic efficacy and enhancing immuno-oncology agents. The company's pipeline also includes the light-activated PINT platform and a flexible RNA delivery system, positioning it at the intersection of drug delivery, immunotherapy, and gene therapy for oncology.
View full company profile